Catalyst
Slingshot members are tracking this event:
Recruitment underway in Phase 1/2 trial of selective cortisol modulator CORT125134 in combination with nab-paclitaxel (Abraxane) to treat solid-tumor cancers
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| CORT | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Aug 02, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Selective Cortisol Modulator, Corti25134, Nab-paclitaxel, Abraxane, Combination, Solid-tumor Cancers
